Cantor Fitzgerald Maintains Overweight on LifeMD, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has maintained an Overweight rating on LifeMD (NASDAQ:LFMD) and increased the price target from $13 to $15.
May 09, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James has reaffirmed an Overweight rating on LifeMD and raised the price target from $13 to $15.
The increase in price target by a reputable analyst suggests a positive outlook on LifeMD's stock, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100